Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Immunol ; 52(1): 149-160, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34695227

RESUMO

During the COVID-19 pandemic, Portugal has experienced three distinct SARS-CoV-2 infection waves. We previously documented the prevalence of SARS-CoV-2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8-18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long-lasting infection immunity against SARS-CoV-2. Moreover, vaccinated people had higher IgG levels from 3 weeks post-vaccination when compared with previously infected people at the same time post-infection.


Assuntos
Anticorpos Antivirais/imunologia , Teste Sorológico para COVID-19 , COVID-19 , Imunoglobulina A/imunologia , Imunoglobulina G/imunologia , SARS-CoV-2/imunologia , Adolescente , Adulto , COVID-19/epidemiologia , COVID-19/imunologia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Portugal/epidemiologia , Prevalência , Fatores de Tempo
2.
Emerg Infect Dis ; 27(11): 2878-2881, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34437830

RESUMO

In September 2020, we tested 13,398 persons in Portugal for antibodies against severe acute respiratory syndrome coronavirus 2 by using a quota sample stratified by age and population density. We found a seroprevalence of 2.2%, 3-4 times larger than the official number of cases at the end of the first wave of the pandemic.


Assuntos
COVID-19 , SARS-CoV-2 , Humanos , Pandemias , Portugal/epidemiologia , Prevalência , Estudos Soroepidemiológicos
3.
Pharmacoeconomics ; 30(12): 1101-17, 2012 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-23116289

RESUMO

The design of decision-analytic models for cost-effectiveness analysis has been the subject of discussion. The current work addresses this issue by noting that, when time is to be explicitly modelled, we need to represent phenomena occurring in continuous time. Models evaluated in continuous time may not have closed-form solutions, and in this case, two approximations can be used: simulation models in continuous time and discretized models at the aggregate level. Stylized examples were set up where both approximations could be implemented. These aimed to illustrate determinants of the use of the two approximations: cycle length and precision, the use of continuity corrections in discretized models and the discretization of rates into probabilities. The examples were also used to explore the impact of the approximations not only in terms of absolute survival but also cost effectiveness and incremental comparisons. Discretized models better approximate continuous time results if lower cycle lengths are used. Continuous time simulation models are inherently stochastic, and the precision of the results is determined by the simulation sample size. The use of continuity corrections in discretized models allows the use of greater cycle lengths, producing no significant bias from the discretization. How the process is discretized (the conversion of rates into probabilities) is key. Results show that appropriate discretization coupled with the use of a continuity correction produces results unbiased for higher cycle lengths. Alternative methods of discretization are less efficient, i.e. lower cycle lengths are needed to obtain unbiased results. The developed work showed the importance of acknowledging bias in estimating cost effectiveness. When the alternative approximations can be applied, we argue that it is preferable to implement a cohort discretized model rather than a simulation model in continuous time. In practice, however, it may not be possible to represent the decision problem by any conventionally defined discretized model, in which case other model designs need to be applied, e.g. a simulation model.


Assuntos
Simulação por Computador , Técnicas de Apoio para a Decisão , Modelos Econômicos , Viés , Análise Custo-Benefício , Humanos , Cadeias de Markov , Probabilidade , Processos Estocásticos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...